News Releases

June 19, 2018 at 5:00 PM EDT

Summary Toggle Marna Borgstrom Joins CryoLife Board of Directors

ATLANTA , June 19, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Marna Borgstrom to its Board of Directors effective immediately. Pat Mackin , Chairman, President, and Chief Executive
June 11, 2018 at 5:08 PM EDT

Summary Toggle CryoLife Announces Peer Review Publication of On-X® Aortic Heart Valve PROACT Study

ATLANTA , June 11, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, today announces the publication of our clinical study entitled "Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement"
May 2, 2018 at 5:24 PM EDT

Summary Toggle CryoLife Reports First Quarter 2018 Results

ATLANTA , May 2, 2018 /PRNewswire/ -- First Quarter and Recent Business Highlights: Total revenues increased 37 percent to $61.9 million in the first quarter of 2018 compared to the first quarter of 2017 Non-GAAP revenues increased 9 percent in the first quarter of 2018 compared to the first
May 1, 2018 at 8:04 AM EDT

Summary Toggle CryoLife to Present at Deutsche Bank 43rd Annual Health Care Conference

ATLANTA , May 1, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in a fireside chat presentation at the upcoming Deutsche Bank 43 rd Annual Health Care Conference on Tuesday, May 8,
April 17, 2018 at 5:04 PM EDT

Summary Toggle CryoLife Announces Release Date and Teleconference Call Details for 2018 First Quarter Financial Results

ATLANTA , April 17, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2018 first quarter financial results will be released on Wednesday, May 2, 2018 after the market closes. On Thursday, May 3, 2018 the
March 20, 2018 at 8:04 AM EDT

Summary Toggle CryoLife to Present at 17th Annual Needham Healthcare Conference

ATLANTA , March 20, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 17 th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at the Westin Grand Central
March 7, 2018 at 6:13 PM EST

Summary Toggle CryoLife Reports Fourth Quarter and Full Year 2017 Results

ATLANTA , March 7, 2018 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Achieved fourth quarter revenues of $52.8 million Achieved double digit revenue growth on a percentage basis in BioGlue ® , On-X, and tissue processing Recorded GAAP net loss of ($3.0) million , or ($0.09) per
February 12, 2018 at 5:04 PM EST

Summary Toggle CryoLife Announces Release Date and Teleconference Call Details for 2017 Fourth Quarter and Year-End Financial Results

ATLANTA , Feb. 12, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2017 fourth quarter and year-end financial results will be released on Wednesday, March 7, 2018 after the market
December 1, 2017 at 5:04 PM EST

Summary Toggle CryoLife Completes Acquisition of JOTEC

ATLANTA , Dec. 1, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of JOTEC AG , a German-based, privately-held developer of
November 6, 2017 at 5:04 PM EST

Summary Toggle CryoLife Announces Enrollment of First Patients in BioGlue® Clinical Trial in China

ATLANTA , Nov. 6, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that enrollment has started in the Company's BioGlue clinical trial in China. The results from the trial will serve as